$155.94
-0.72-0.46%
Ult. Agg.: Nov 6, 7:45 PM
The average analyst price target for Alnylam Pharmaceuticals is $382.41, 146.0% above the current price. Of 23 analysts, 19 rate it Buy and 4 Hold. Targets range from $199 to $583. The latest change came on Nov 2, 2026, when Barclays lowered its price target on Alnylam Pharmaceuticals from $450 to $380 and kept an Overweight rating.
Price Target Range — 6 Quarters
Analyst Consensus — 23 Analysts
Rating Trend — Last 9 Months